INV-88
/ Innovimmune Biotherap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 09, 2022
Design and discovery of novel oral INV-88 macrophage migration inhibitory factor (MIF) inhibitors: Potent anti-tumor activity in vitro and in vivo
(AACR 2022)
- "The data presented highlight the potential therapeutic utility of pharmacological MIF inhibition with oral INV-88 new chemical entities as a novel immunotherapeutic treatment modality for cancer."
IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Melanoma • Oncology • Solid Tumor • BCL2 • CASP3 • CASP7 • CD44 • CD74 • CXCL8 • IL1B • IL6 • MIF • TNFA
1 to 1
Of
1
Go to page
1